These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29369397)

  • 1. Metallothioneins are neuroprotective agents in lysosomal storage disorders.
    Cavalca E; Cesani M; Gifford JC; Sena-Esteves M; Terreni MR; Leoncini G; Peviani M; Biffi A
    Ann Neurol; 2018 Feb; 83(2):418-432. PubMed ID: 29369397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metallothioneins as dynamic markers for brain disease in lysosomal disorders.
    Cesani M; Cavalca E; Macco R; Leoncini G; Terreni MR; Lorioli L; Furlan R; Comi G; Doglioni C; Zacchetti D; Sessa M; Scherzer CR; Biffi A
    Ann Neurol; 2014 Jan; 75(1):127-37. PubMed ID: 24242821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metallothionein prevents neurodegeneration and central nervous system cell death after treatment with gliotoxin 6-aminonicotinamide.
    Penkowa M; Quintana A; Carrasco J; Giralt M; Molinero A; Hidalgo J
    J Neurosci Res; 2004 Jul; 77(1):35-53. PubMed ID: 15197737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
    Biffi A
    Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
    Seregin SS; Amalfitano A
    Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy in astrocytes: a novel culprit in lysosomal storage disorders.
    Di Malta C; Fryer JD; Settembre C; Ballabio A
    Autophagy; 2012 Dec; 8(12):1871-2. PubMed ID: 23047468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metallothioneins I and II: neuroprotective significance during CNS pathology.
    Stankovic RK; Chung RS; Penkowa M
    Int J Biochem Cell Biol; 2007; 39(3):484-9. PubMed ID: 17097331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia.
    Wakida K; Shimazawa M; Hozumi I; Satoh M; Nagase H; Inuzuka T; Hara H
    Neuroscience; 2007 Aug; 148(1):105-14. PubMed ID: 17624681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipocalin-type prostaglandin D synthase is up-regulated in oligodendrocytes in lysosomal storage diseases and binds gangliosides.
    Mohri I; Taniike M; Okazaki I; Kagitani-Shimono K; Aritake K; Kanekiyo T; Yagi T; Takikita S; Kim HS; Urade Y; Suzuki K
    J Neurochem; 2006 May; 97(3):641-51. PubMed ID: 16515539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.
    Roca C; Motas S; Marcó S; Ribera A; Sánchez V; Sánchez X; Bertolin J; León X; Pérez J; Garcia M; Villacampa P; Ruberte J; Pujol A; Haurigot V; Bosch F
    Hum Mol Genet; 2017 Apr; 26(8):1535-1551. PubMed ID: 28334745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lysosomal storage diseases: A brief summary].
    Bornemann A; Harzer K
    Pathologe; 2015 Sep; 36(5):485-93. PubMed ID: 26314267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lysosomal storage diseases--an overview].
    Kloska A; Tylki-Szymańska A; Wegrzyn G
    Postepy Biochem; 2011; 57(2):128-32. PubMed ID: 21913413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival study of metallothionein-1 transgenic mice and respective controls (C57BL/6J): influence of a zinc-enriched environment.
    Malavolta M; Basso A; Piacenza F; Giacconi R; Costarelli L; Pierpaoli S; Mocchegiani E
    Rejuvenation Res; 2012 Apr; 15(2):140-3. PubMed ID: 22533418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune system irregularities in lysosomal storage disorders.
    Castaneda JA; Lim MJ; Cooper JD; Pearce DA
    Acta Neuropathol; 2008 Feb; 115(2):159-74. PubMed ID: 17924126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for lysosomal storage diseases and peroxisomal diseases.
    Ohashi T
    J Hum Genet; 2019 Feb; 64(2):139-143. PubMed ID: 30498239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
    Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
    FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metallothionein-I and -III expression in animal models of Alzheimer disease.
    Carrasco J; Adlard P; Cotman C; Quintana A; Penkowa M; Xu F; Van Nostrand WE; Hidalgo J
    Neuroscience; 2006 Dec; 143(4):911-22. PubMed ID: 17027170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of metallothioneins as danger signals in the pathogenesis of colitis.
    Devisscher L; Hindryckx P; Lynes MA; Waeytens A; Cuvelier C; De Vos F; Vanhove C; Vos MD; Laukens D
    J Pathol; 2014 May; 233(1):89-100. PubMed ID: 24452846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal storage disorders: old diseases, present and future challenges.
    Klein AD; Futerman AH
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():59-63. PubMed ID: 24380123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases.
    Saffari A; Kölker S; Hoffmann GF; Ebrahimi-Fakhari D
    J Inherit Metab Dis; 2017 Sep; 40(5):631-640. PubMed ID: 28477283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.